Efficacy and safety of pembrolizumab and radiotherapy in relapsed/ refractory cutaneous T cell lymphoma: results of the PORT trial

S. Morris; J. Scarisbrick; A. Arumainathan; A. Bates; E. Cheadle; G. Collins; R. Cowan; N. El-Mehidi; N. O'Rourke; W. Osbourne; J. Pawade; S. Robinson; C. Tyson; J. Ward; S. Whittaker; W. Wilson; T. Illidge

doi:10.1016/j.ejca.2024.114386

Efficacy and safety of pembrolizumab and radiotherapy in relapsed/ refractory cutaneous T cell lymphoma: results of the PORT trial

S. Morris, J. Scarisbrick, A. Arumainathan, A. Bates, E. Cheadle, G. Collins, R. Cowan, N. El-Mehidi, N. O'Rourke, W. Osbourne, J. Pawade, S. Robinson, C. Tyson, J. Ward, S. Whittaker, W. Wilson, T. Illidge

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	114386
Pages (from-to)	S22-S23
Number of pages	2
Journal	European Journal of Cancer
Volume	211
DOIs	https://doi.org/10.1016/j.ejca.2024.114386
Publication status	Published - Oct 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejca.2024.114386

Cite this

Morris, S., Scarisbrick, J., Arumainathan, A., Bates, A., Cheadle, E., Collins, G., Cowan, R., El-Mehidi, N., O'Rourke, N., Osbourne, W., Pawade, J., Robinson, S., Tyson, C., Ward, J., Whittaker, S., Wilson, W., & Illidge, T. (2024). Efficacy and safety of pembrolizumab and radiotherapy in relapsed/ refractory cutaneous T cell lymphoma: results of the PORT trial. European Journal of Cancer, 211, S22-S23. Article 114386. https://doi.org/10.1016/j.ejca.2024.114386

@article{9cd795c76a3645e9bd73d0e31a2274f5,

title = "Efficacy and safety of pembrolizumab and radiotherapy in relapsed/ refractory cutaneous T cell lymphoma: results of the PORT trial",

author = "S. Morris and J. Scarisbrick and A. Arumainathan and A. Bates and E. Cheadle and G. Collins and R. Cowan and N. El-Mehidi and N. O'Rourke and W. Osbourne and J. Pawade and S. Robinson and C. Tyson and J. Ward and S. Whittaker and W. Wilson and T. Illidge",

year = "2024",

month = oct,

doi = "10.1016/j.ejca.2024.114386",

language = "English",

volume = "211",

pages = "S22--S23",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier BV",

}

Morris, S, Scarisbrick, J, Arumainathan, A, Bates, A, Cheadle, E, Collins, G, Cowan, R, El-Mehidi, N, O'Rourke, N, Osbourne, W, Pawade, J, Robinson, S, Tyson, C, Ward, J, Whittaker, S, Wilson, W & Illidge, T 2024, 'Efficacy and safety of pembrolizumab and radiotherapy in relapsed/ refractory cutaneous T cell lymphoma: results of the PORT trial', European Journal of Cancer, vol. 211, 114386, pp. S22-S23. https://doi.org/10.1016/j.ejca.2024.114386

TY - JOUR

T1 - Efficacy and safety of pembrolizumab and radiotherapy in relapsed/ refractory cutaneous T cell lymphoma

T2 - results of the PORT trial

AU - Morris, S.

AU - Scarisbrick, J.

AU - Arumainathan, A.

AU - Bates, A.

AU - Cheadle, E.

AU - Collins, G.

AU - Cowan, R.

AU - El-Mehidi, N.

AU - O'Rourke, N.

AU - Osbourne, W.

AU - Pawade, J.

AU - Robinson, S.

AU - Tyson, C.

AU - Ward, J.

AU - Whittaker, S.

AU - Wilson, W.

AU - Illidge, T.

PY - 2024/10

Y1 - 2024/10

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:001330761900048&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1016/j.ejca.2024.114386

DO - 10.1016/j.ejca.2024.114386

M3 - Meeting Abstract

SN - 0959-8049

VL - 211

SP - S22-S23

JO - European Journal of Cancer

JF - European Journal of Cancer

M1 - 114386

ER -

Efficacy and safety of pembrolizumab and radiotherapy in relapsed/ refractory cutaneous T cell lymphoma: results of the PORT trial

UN SDGs

Access to Document

Other files and links

Cite this